• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

循环 microRNAs 预测三阴性乳腺癌的复发风险。

Circulating Micro-RNAs Predict the Risk of Recurrence in Triple-Negative Breast Cancer.

机构信息

Institute of Clinical Medicine, Clinical Pathology and Forensic Medicine, University of Eastern Finland, FI-70211 Kuopio, Finland.

Cancer Center, Department of Oncology, Kuopio University Hospital, FI-70029 Kuopio, Finland.

出版信息

Cells. 2024 Nov 14;13(22):1884. doi: 10.3390/cells13221884.

DOI:10.3390/cells13221884
PMID:39594632
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11593277/
Abstract

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with a high tendency for developing a recurrent disease. Circulating micro-RNAs (cmiRNAs) obtained through liquid biopsy are potential prognostic biomarkers for the assessment of TNBC recurrence risk. In this study, we sequenced cmiRNAs from the serum samples of 14 recurrent and 19 non-recurrent TNBC cases and compared expression profiles in relation to recurrence status, survival data and miRNA expression in matched tumor samples. Differential expression analysis between recurrent and non-recurrent cases identified ten differentially expressed (DE) cmiRNAs, of which cmiRNAs miR-21-5p ( = 0.030, HR = 1.87, 95% CI 1.06-3.30), miR-16-5p ( = 0.032, HR = 0.53, 95% CI 0.30-0.95), and miR-26b-5p ( = 0.023, HR = 0.52, 95% CI 0.29-0.91) were associated with recurrence-free survival in multivariable survival analysis. Expression profiles of matched tumor and serum samples were shown to correlate with each other. DE cmiRNAs were associated with common cancer-related signaling pathways and improved the overall predictive performance of the logistic regression model assessing the recurrence risk. Our results indicate that recurrent and non-recurrent TNBC differ in their cmiRNA expression profiles, and that three specific cmiRNAs can be used to assess the risk of recurrence in TNBC.

摘要

三阴性乳腺癌(TNBC)是一种侵袭性乳腺癌亚型,具有较高的复发倾向。通过液体活检获得的循环 microRNA(cmiRNA)是评估 TNBC 复发风险的潜在预后生物标志物。在这项研究中,我们对 14 例复发和 19 例非复发 TNBC 病例的血清样本进行了 cmiRNA 测序,并比较了与复发状态、生存数据和匹配肿瘤样本中 miRNA 表达相关的表达谱。复发和非复发病例之间的差异表达分析确定了十个差异表达(DE)的 cmiRNA,其中 cmiRNA miR-21-5p( = 0.030,HR = 1.87,95%CI 1.06-3.30)、miR-16-5p( = 0.032,HR = 0.53,95%CI 0.30-0.95)和 miR-26b-5p( = 0.023,HR = 0.52,95%CI 0.29-0.91)与多变量生存分析中的无复发生存相关。匹配的肿瘤和血清样本的表达谱显示彼此相关。DE cmiRNA 与常见的癌症相关信号通路相关,并提高了评估复发风险的逻辑回归模型的整体预测性能。我们的研究结果表明,复发和非复发的 TNBC 在其 cmiRNA 表达谱上存在差异,并且三种特定的 cmiRNA 可用于评估 TNBC 的复发风险。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/416c/11593277/b322cea78e46/cells-13-01884-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/416c/11593277/8296a4dd5ed8/cells-13-01884-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/416c/11593277/cdef6e352f04/cells-13-01884-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/416c/11593277/b322cea78e46/cells-13-01884-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/416c/11593277/8296a4dd5ed8/cells-13-01884-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/416c/11593277/cdef6e352f04/cells-13-01884-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/416c/11593277/b322cea78e46/cells-13-01884-g003.jpg

相似文献

1
Circulating Micro-RNAs Predict the Risk of Recurrence in Triple-Negative Breast Cancer.循环 microRNAs 预测三阴性乳腺癌的复发风险。
Cells. 2024 Nov 14;13(22):1884. doi: 10.3390/cells13221884.
2
A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients.血清 microRNA 特征可预测三阴性乳腺癌患者的肿瘤复发和生存。
Clin Cancer Res. 2015 Mar 1;21(5):1207-14. doi: 10.1158/1078-0432.CCR-14-2011. Epub 2014 Dec 29.
3
Clinical Identification of Dysregulated Circulating microRNAs and Their Implication in Drug Response in Triple Negative Breast Cancer (TNBC) by Target Gene Network and Meta-Analysis.通过靶向基因网络和荟萃分析鉴定三阴性乳腺癌 (TNBC) 中失调的循环 microRNAs 及其对药物反应的影响的临床研究
Genes (Basel). 2021 Apr 9;12(4):549. doi: 10.3390/genes12040549.
4
A panel of eight microRNAs is a good predictive parameter for triple-negative breast cancer relapse.一个由八个 microRNAs 组成的面板是预测三阴性乳腺癌复发的一个很好的预测参数。
Theranostics. 2020 Jul 9;10(19):8771-8789. doi: 10.7150/thno.46142. eCollection 2020.
5
Identification of Specific miRNA Signature in Paired Sera and Tissue Samples of Indian Women with Triple Negative Breast Cancer.印度三阴性乳腺癌女性配对血清和组织样本中特定miRNA特征的鉴定
PLoS One. 2016 Jul 12;11(7):e0158946. doi: 10.1371/journal.pone.0158946. eCollection 2016.
6
Identification of tRNA-derived small noncoding RNAs as potential biomarkers for prediction of recurrence in triple-negative breast cancer.鉴定 tRNA 衍生的小非编码 RNA 作为预测三阴性乳腺癌复发的潜在生物标志物。
Cancer Med. 2018 Oct;7(10):5130-5144. doi: 10.1002/cam4.1761. Epub 2018 Sep 21.
7
Detection of Human Circulating and Extracellular Vesicle-Derived miRNAs in Serum of Humanized Mice Transplanted with Human Breast Cancer (HER2 and TNBC) Cells-A Proof of Principle Investigation.在移植了人乳腺癌(HER2和三阴乳腺癌)细胞的人源化小鼠血清中检测人循环和细胞外囊泡衍生的微小RNA——一项原理验证研究
Int J Mol Sci. 2025 Apr 11;26(8):3629. doi: 10.3390/ijms26083629.
8
Circulating cell-free miRNAs as biomarker for triple-negative breast cancer.循环游离微小RNA作为三阴性乳腺癌的生物标志物
Br J Cancer. 2015 May 26;112(11):1751-9. doi: 10.1038/bjc.2015.143. Epub 2015 Apr 23.
9
Circulating Pre-microRNA-488 in Peripheral Blood Is a Potential Biomarker for Predicting Recurrence in Breast Cancer.外周血中循环前体微小RNA-488是预测乳腺癌复发的潜在生物标志物。
Anticancer Res. 2018 Aug;38(8):4515-4523. doi: 10.21873/anticanres.12755.
10
Low Expression of Circulating MicroRNA-34c is Associated with Poor Prognosis in Triple-Negative Breast Cancer.循环微小RNA-34c低表达与三阴性乳腺癌预后不良相关。
Yonsei Med J. 2017 Jul;58(4):697-702. doi: 10.3349/ymj.2017.58.4.697.

引用本文的文献

1
Decoding the Epigenome: Comparative Analysis of Uterine Leiomyosarcoma and Leiomyoma.解读表观基因组:子宫平滑肌肉瘤与平滑肌瘤的比较分析
Cancers (Basel). 2025 Aug 9;17(16):2610. doi: 10.3390/cancers17162610.
2
Circulating Tumor Cell Detection for Therapeutic and Prognostic Roles in Breast Cancer.循环肿瘤细胞检测在乳腺癌治疗和预后中的作用
Cancer Med. 2025 Jun;14(11):e70902. doi: 10.1002/cam4.70902.

本文引用的文献

1
Circulating miR-221/222 expression as microRNA biomarker predicting tamoxifen treatment outcome: a case-control study.循环miR-221/222表达作为预测他莫昔芬治疗结果的微小RNA生物标志物:一项病例对照研究。
Ann Med Surg (Lond). 2023 Jul 10;85(8):3806-3815. doi: 10.1097/MS9.0000000000001061. eCollection 2023 Aug.
2
DIANA-miRPath v4.0: expanding target-based miRNA functional analysis in cell-type and tissue contexts.DIANA-miRPath v4.0:在细胞类型和组织背景下扩展基于靶标的 miRNA 功能分析。
Nucleic Acids Res. 2023 Jul 5;51(W1):W154-W159. doi: 10.1093/nar/gkad431.
3
End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO.
新辅助治疗结束时循环微小RNA与HER2阳性乳腺癌患者预后:来自NeoALTTO的探索性分析
Front Oncol. 2023 Jan 31;12:1028825. doi: 10.3389/fonc.2022.1028825. eCollection 2022.
4
Evaluating the Role of Circulating MicroRNAs in Predicting Long-Term Survival Outcomes in Breast Cancer: A Prospective, Multicenter Clinical Trial.评估循环 microRNAs 在预测乳腺癌长期生存结局中的作用:一项前瞻性、多中心临床试验。
J Am Coll Surg. 2023 Feb 1;236(2):317-327. doi: 10.1097/XCS.0000000000000465. Epub 2022 Nov 2.
5
A review on the role of mir-16-5p in the carcinogenesis.关于mir-16-5p在致癌作用中的作用综述。
Cancer Cell Int. 2022 Nov 8;22(1):342. doi: 10.1186/s12935-022-02754-0.
6
Prediction of axillary lymph node metastasis in triple-negative breast cancer by multi-omics analysis and an integrated model.通过多组学分析和综合模型预测三阴性乳腺癌腋窝淋巴结转移
Ann Transl Med. 2022 Jun;10(11):623. doi: 10.21037/atm-22-277.
7
Deciphering Tumour Heterogeneity: From Tissue to Liquid Biopsy.解读肿瘤异质性:从组织活检到液体活检
Cancers (Basel). 2022 Mar 8;14(6):1384. doi: 10.3390/cancers14061384.
8
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.帕博利珠单抗治疗早期三阴性乳腺癌无事件生存。
N Engl J Med. 2022 Feb 10;386(6):556-567. doi: 10.1056/NEJMoa2112651.
9
MiR-26b-5p inhibits cell proliferation and EMT by targeting MYCBP in triple-negative breast cancer.miR-26b-5p 通过靶向 MYCBP 抑制三阴性乳腺癌中的细胞增殖和 EMT。
Cell Mol Biol Lett. 2021 Dec 11;26(1):52. doi: 10.1186/s11658-021-00288-3.
10
Role of PTEN, PI3K, and mTOR in Triple-Negative Breast Cancer.PTEN、PI3K和mTOR在三阴性乳腺癌中的作用。
Life (Basel). 2021 Nov 17;11(11):1247. doi: 10.3390/life11111247.